Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 176

1.

PARP inhibition in BRCA2-mutated prostate cancer.

Nientiedt C, Tolstov Y, Volckmar AL, Endris V, Bonekamp D, Haberkorn U, Jäger D, Sültmann H, Stenzinger A, Hohenfellner M, Grüllich C, Duensing S.

Ann Oncol. 2017 Jan 1;28(1):189-191. doi: 10.1093/annonc/mdw445. No abstract available.

PMID:
31792512
2.

Patients resistant against PSMA-targeting alpha-radiation therapy often harbor mutations in DNA-repair associated genes.

Kratochwil C, Giesel FL, Heussel CP, Kazdal D, Endris V, Nientiedt C, Bruchertseifer F, Kippenberger M, Rathke H, Leichsenring J, Hohenfellner M, Morgenstern A, Haberkorn U, Duensing S, Stenzinger A.

J Nucl Med. 2019 Oct 10. pii: jnumed.119.234559. doi: 10.2967/jnumed.119.234559. [Epub ahead of print]

PMID:
31601699
3.

The BRCA2 mutation status shapes the immune phenotype of prostate cancer.

Jenzer M, Keß P, Nientiedt C, Endris V, Kippenberger M, Leichsenring J, Stögbauer F, Haimes J, Mishkin S, Kudlow B, Kaczorowski A, Zschäbitz S, Volckmar AL, Sültmann H, Jäger D, Duensing A, Schirmacher P, Hohenfellner M, Grüllich C, Stenzinger A, Duensing S.

Cancer Immunol Immunother. 2019 Oct;68(10):1621-1633. doi: 10.1007/s00262-019-02393-x. Epub 2019 Sep 23.

4.

Increased mediator complex subunit CDK19 expression associates with aggressive prostate cancer.

Becker F, Joerg V, Hupe MC, Roth D, Krupar R, Lubczyk V, Kuefer R, Sailer V, Duensing S, Kirfel J, Merseburger AS, Brägelmann J, Perner S, Offermann A.

Int J Cancer. 2020 Jan 15;146(2):577-588. doi: 10.1002/ijc.32551. Epub 2019 Jul 19.

PMID:
31271443
5.

Comparative Analysis of AR Variant AR-V567es mRNA Detection Systems Reveals Eminent Variability and Questions the Role as a Clinical Biomarker in Prostate Cancer.

Bernemann C, Humberg V, Thielen B, Steinestel J, Chen X, Duensing S, Schrader AJ, Boegemann M.

Clin Cancer Res. 2019 Jul 1;25(13):3856-3864. doi: 10.1158/1078-0432.CCR-18-4276. Epub 2019 Apr 16.

PMID:
30992298
6.

Standardized Magnetic Resonance Imaging Reporting Using the Prostate Cancer Radiological Estimation of Change in Sequential Evaluation Criteria and Magnetic Resonance Imaging/Transrectal Ultrasound Fusion with Transperineal Saturation Biopsy to Select Men on Active Surveillance.

Dieffenbacher S, Nyarangi-Dix J, Giganti F, Bonekamp D, Kesch C, Müller-Wolf MB, Schütz V, Gasch C, Hatiboglu G, Hauffe M, Stenzinger A, Duensing S, Schlemmer HP, Moore CM, Hohenfellner M, Radtke JP.

Eur Urol Focus. 2019 Mar 13. pii: S2405-4569(19)30076-8. doi: 10.1016/j.euf.2019.03.001. [Epub ahead of print]

PMID:
30878348
7.

Cullin 5 is a novel candidate tumor suppressor in renal cell carcinoma involved in the maintenance of genome stability.

Tapia-Laliena MÁ, Korzeniewski N, Peña-Llopis S, Scholl C, Fröhling S, Hohenfellner M, Duensing A, Duensing S.

Oncogenesis. 2019 Jan 9;8(1):4. doi: 10.1038/s41389-018-0110-2.

8.

Expression of Prostate-Specific Membrane Antigen (PSMA) on Biopsies Is an Independent Risk Stratifier of Prostate Cancer Patients at Time of Initial Diagnosis.

Hupe MC, Philippi C, Roth D, Kümpers C, Ribbat-Idel J, Becker F, Joerg V, Duensing S, Lubczyk VH, Kirfel J, Sailer V, Kuefer R, Merseburger AS, Perner S, Offermann A.

Front Oncol. 2018 Dec 20;8:623. doi: 10.3389/fonc.2018.00623. eCollection 2018.

9.

Combined Clinical Parameters and Multiparametric Magnetic Resonance Imaging for the Prediction of Extraprostatic Disease-A Risk Model for Patient-tailored Risk Stratification When Planning Radical Prostatectomy.

Nyarangi-Dix J, Wiesenfarth M, Bonekamp D, Hitthaler B, Schütz V, Dieffenbacher S, Mueller-Wolf M, Roth W, Stenzinger A, Duensing S, Roethke M, Teber D, Schlemmer HP, Hohenfellner M, Radtke JP.

Eur Urol Focus. 2018 Nov 23. pii: S2405-4569(18)30336-5. doi: 10.1016/j.euf.2018.11.004. [Epub ahead of print]

PMID:
30477971
10.

Correlation between genomic index lesions and mpMRI and 68Ga-PSMA-PET/CT imaging features in primary prostate cancer.

Kesch C, Radtke JP, Wintsche A, Wiesenfarth M, Luttje M, Gasch C, Dieffenbacher S, Pecqueux C, Teber D, Hatiboglu G, Nyarangi-Dix J, Simpfendörfer T, Schönberg G, Dimitrakopoulou-Strauss A, Freitag M, Duensing A, Grüllich C, Jäger D, Götz M, Grabe N, Schweiger MR, Pahernik S, Perner S, Herpel E, Roth W, Wieczorek K, Maier-Hein K, Debus J, Haberkorn U, Giesel F, Galle J, Hadaschik B, Schlemmer HP, Hohenfellner M, Bonekamp D, Sültmann H, Duensing S.

Sci Rep. 2018 Nov 12;8(1):16708. doi: 10.1038/s41598-018-35058-3.

11.

FGF-2 is a driving force for chromosomal instability and a stromal factor associated with adverse clinico-pathological features in prostate cancer.

Pecqueux C, Arslan A, Heller M, Falkenstein M, Kaczorowski A, Tolstov Y, Sültmann H, Grüllich C, Herpel E, Duensing A, Kristiansen G, Hohenfellner M, Navone NM, Duensing S.

Urol Oncol. 2018 Aug;36(8):365.e15-365.e26. doi: 10.1016/j.urolonc.2018.05.020. Epub 2018 Jun 7.

PMID:
29887238
12.

Prospective single center trial of next-generation sequencing analysis in metastatic renal cell cancer: the MORE-TRIAL.

Dieffenbacher S, Zschäbitz S, Hofer L, Hatiboglu G, Hou W, Hohenfellner M, Duensing S, Sültmann H, Pahernik S, Grüllich C.

Future Sci OA. 2018 Mar 14;4(5):FSO299. doi: 10.4155/fsoa-2017-0150. eCollection 2018 Jun. Review.

13.

Genomic features of renal cell carcinoma with venous tumor thrombus.

Warsow G, Hübschmann D, Kleinheinz K, Nientiedt C, Heller M, Van Coile L, Tolstov Y, Trennheuser L, Wieczorek K, Pecqueux C, Gasch C, Kuru T, Nyarangi-Dix J, Hatiboglu G, Teber D, Perner S, Stenzinger A, Roth W, Hadaschik B, Pahernik S, Jäger D, Grüllich C, Duensing A, Eils R, Schlesner M, Sültmann H, Hohenfellner M, Duensing S.

Sci Rep. 2018 May 10;8(1):7477. doi: 10.1038/s41598-018-25544-z.

14.

[The impact of the androgen receptor splice variant AR-V7 on the prognosis and treatment of advanced prostate cancer].

Thelen P, Taubert H, Duensing S, Kristiansen G, Merseburger AS, Cronauer MV.

Aktuelle Urol. 2018 Jan 25. doi: 10.1055/s-0043-115426. [Epub ahead of print] German.

PMID:
29370587
15.

Overexpression of nuclear AR-V7 protein in primary prostate cancer is an independent negative prognostic marker in men with high-risk disease receiving adjuvant therapy.

Chen X, Bernemann C, Tolkach Y, Heller M, Nientiedt C, Falkenstein M, Herpel E, Jenzer M, Grüllich C, Jäger D, Sültmann H, Duensing A, Perner S, Cronauer MV, Stephan C, Debus J, Schrader AJ, Kristiansen G, Hohenfellner M, Duensing S.

Urol Oncol. 2018 Apr;36(4):161.e19-161.e30. doi: 10.1016/j.urolonc.2017.11.001. Epub 2017 Dec 1.

PMID:
29198908
16.

APOBEC3A Expression in Penile Squamous Cell Carcinoma.

Heller M, Prigge ES, Kaczorowski A, von Knebel Doeberitz M, Hohenfellner M, Duensing S.

Pathobiology. 2018;85(3):169-178. doi: 10.1159/000479007. Epub 2017 Nov 23.

17.

Patient-specific molecular alterations are associated with metastatic clear cell renal cell cancer progressing under tyrosine kinase inhibitor therapy.

Dietz S, Sültmann H, Du Y, Reisinger E, Riediger AL, Volckmar AL, Stenzinger A, Schlesner M, Jäger D, Hohenfellner M, Duensing S, Grüllich C, Pahernik S.

Oncotarget. 2017 May 23;8(43):74049-74057. doi: 10.18632/oncotarget.18200. eCollection 2017 Sep 26.

18.

Prognostic Value of the New Prostate Cancer International Society of Urological Pathology Grade Groups.

Offermann A, Hohensteiner S, Kuempers C, Ribbat-Idel J, Schneider F, Becker F, Hupe MC, Duensing S, Merseburger AS, Kirfel J, Reischl M, Lubczyk V, Kuefer R, Perner S.

Front Med (Lausanne). 2017 Sep 29;4:157. doi: 10.3389/fmed.2017.00157. eCollection 2017.

19.

Mutations in BRCA2 and taxane resistance in prostate cancer.

Nientiedt C, Heller M, Endris V, Volckmar AL, Zschäbitz S, Tapia-Laliena MA, Duensing A, Jäger D, Schirmacher P, Sültmann H, Stenzinger A, Hohenfellner M, Grüllich C, Duensing S.

Sci Rep. 2017 Jul 4;7(1):4574. doi: 10.1038/s41598-017-04897-x.

20.

Cyclin K dependent regulation of Aurora B affects apoptosis and proliferation by induction of mitotic catastrophe in prostate cancer.

Schecher S, Walter B, Falkenstein M, Macher-Goeppinger S, Stenzel P, Krümpelmann K, Hadaschik B, Perner S, Kristiansen G, Duensing S, Roth W, Tagscherer KE.

Int J Cancer. 2017 Oct 15;141(8):1643-1653. doi: 10.1002/ijc.30864. Epub 2017 Jul 12.

21.

Intraindividual Comparison of 18F-PSMA-1007 PET/CT, Multiparametric MRI, and Radical Prostatectomy Specimens in Patients with Primary Prostate Cancer: A Retrospective, Proof-of-Concept Study.

Kesch C, Vinsensia M, Radtke JP, Schlemmer HP, Heller M, Ellert E, Holland-Letz T, Duensing S, Grabe N, Afshar-Oromieh A, Wieczorek K, Schäfer M, Neels OC, Cardinale J, Kratochwil C, Hohenfellner M, Kopka K, Haberkorn U, Hadaschik BA, Giesel FL.

J Nucl Med. 2017 Nov;58(11):1805-1810. doi: 10.2967/jnumed.116.189233. Epub 2017 May 4. Erratum in: J Nucl Med. 2019 Apr;60(4):554.

22.

TMPRSS2:ERG gene fusion variants induce TGF-β signaling and epithelial to mesenchymal transition in human prostate cancer cells.

Ratz L, Laible M, Kacprzyk LA, Wittig-Blaich SM, Tolstov Y, Duensing S, Altevogt P, Klauck SM, Sültmann H.

Oncotarget. 2017 Apr 11;8(15):25115-25130. doi: 10.18632/oncotarget.15931.

23.

Combined Clinical Parameters and Multiparametric Magnetic Resonance Imaging for Advanced Risk Modeling of Prostate Cancer-Patient-tailored Risk Stratification Can Reduce Unnecessary Biopsies.

Radtke JP, Wiesenfarth M, Kesch C, Freitag MT, Alt CD, Celik K, Distler F, Roth W, Wieczorek K, Stock C, Duensing S, Roethke MC, Teber D, Schlemmer HP, Hohenfellner M, Bonekamp D, Hadaschik BA.

Eur Urol. 2017 Dec;72(6):888-896. doi: 10.1016/j.eururo.2017.03.039. Epub 2017 Apr 8.

PMID:
28400169
24.

Efficacy of Cabazitaxel Treatment in Metastatic Castration Resistant Prostate Cancer in Second and Later Lines. An Experience from Two German Centers.

Zschäbitz S, Vallet S, Hadaschik B, Debatin D, Fuxius S, Karcher A, Pahernik S, Spath C, Duensing S, Jäger D, Hohenfellner M, Grüllich C.

J Cancer. 2017 Feb 11;8(4):507-512. doi: 10.7150/jca.17644. eCollection 2017.

25.

[Level IV inferior vena cava tumor thrombus : A rare diagnosis in patients with renal cell carcinoma].

Hofer L, Gasch C, Hatiboglu G, Motsch J, Grüllich C, Duensing S, Hohenfellner M.

Urologe A. 2017 Jul;56(7):868-875. doi: 10.1007/s00120-017-0369-5. German.

PMID:
28349189
26.

Effective downsizing but enhanced intratumoral heterogeneity following neoadjuvant sorafenib in patients with non-metastatic renal cell carcinoma.

Hatiboglu G, Hohenfellner M, Arslan A, Hadaschik B, Teber D, Radtke JP, Hallscheidt P, Tolstov Y, Roth W, Grüllich C, Huesing J, Duensing S, Pahernik S.

Langenbecks Arch Surg. 2017 Jun;402(4):637-644. doi: 10.1007/s00423-016-1543-8. Epub 2016 Dec 23.

PMID:
28012035
27.

MED15 overexpression in prostate cancer arises during androgen deprivation therapy via PI3K/mTOR signaling.

Offermann A, Vlasic I, Syring I, Vogel W, Ruiz C, Zellweger T, Rentsch CA, Hagedorn S, Behrends J, Nowak M, Merseburger A, Bubendorf L, Kirfel J, Duensing S, Shaikhibrahim Z, Perner S.

Oncotarget. 2017 Jan 31;8(5):7964-7976. doi: 10.18632/oncotarget.13860.

28.

F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients.

Giesel FL, Hadaschik B, Cardinale J, Radtke J, Vinsensia M, Lehnert W, Kesch C, Tolstov Y, Singer S, Grabe N, Duensing S, Schäfer M, Neels OC, Mier W, Haberkorn U, Kopka K, Kratochwil C.

Eur J Nucl Med Mol Imaging. 2017 Apr;44(4):678-688. doi: 10.1007/s00259-016-3573-4. Epub 2016 Nov 26.

29.

Impact of resection and systemic therapy on the survival of patients with brain metastasis of metastatic renal cell carcinoma.

Du Y, Pahernik S, Hadaschik B, Teber D, Duensing S, Jäger D, Hohenfellner M, Grüllich C.

J Neurooncol. 2016 Oct;130(1):221-228. Epub 2016 Aug 18.

PMID:
27538910
30.

Molecular complexity of taxane-induced cytotoxicity in prostate cancer cells.

Mang J, Merkle K, Heller M, Schüler J, Tolstov Y, Li J, Hohenfellner M, Duensing S.

Urol Oncol. 2017 Jan;35(1):32.e9-32.e16. doi: 10.1016/j.urolonc.2016.07.017. Epub 2016 Sep 28.

PMID:
27692847
31.

PARP inhibition in BRCA2-mutated prostate cancer.

Nientiedt C, Tolstov Y, Volckmar AL, Endris V, Bonekamp D, Haberkorn U, Jäger D, Sültmann H, Stenzinger A, Hohenfellner M, Grüllich C, Duensing S.

Ann Oncol. 2017 Jan 1;28(1):189-191. doi: 10.1093/annonc/mdw445. No abstract available.

PMID:
27687312
32.

Pan-Cancer Analysis of the Mediator Complex Transcriptome Identifies CDK19 and CDK8 as Therapeutic Targets in Advanced Prostate Cancer.

Brägelmann J, Klümper N, Offermann A, von Mässenhausen A, Böhm D, Deng M, Queisser A, Sanders C, Syring I, Merseburger AS, Vogel W, Sievers E, Vlasic I, Carlsson J, Andrén O, Brossart P, Duensing S, Svensson MA, Shaikhibrahim Z, Kirfel J, Perner S.

Clin Cancer Res. 2017 Apr 1;23(7):1829-1840. doi: 10.1158/1078-0432.CCR-16-0094. Epub 2016 Sep 27.

33.

Ecotropic viral integration site 1, a novel oncogene in prostate cancer.

Queisser A, Hagedorn S, Wang H, Schaefer T, Konantz M, Alavi S, Deng M, Vogel W, von Mässenhausen A, Kristiansen G, Duensing S, Kirfel J, Lengerke C, Perner S.

Oncogene. 2017 Mar;36(11):1573-1584. doi: 10.1038/onc.2016.325. Epub 2016 Sep 12.

PMID:
27617580
34.

Ago-RIP-Seq identifies Polycomb repressive complex I member CBX7 as a major target of miR-375 in prostate cancer progression.

Pickl JM, Tichy D, Kuryshev VY, Tolstov Y, Falkenstein M, Schüler J, Reidenbach D, Hotz-Wagenblatt A, Kristiansen G, Roth W, Hadaschik B, Hohenfellner M, Duensing S, Heckmann D, Sültmann H.

Oncotarget. 2016 Sep 13;7(37):59589-59603. doi: 10.18632/oncotarget.10729.

35.

Targeting DDR2 in head and neck squamous cell carcinoma with dasatinib.

von Mässenhausen A, Sanders C, Brägelmann J, Konantz M, Queisser A, Vogel W, Kristiansen G, Duensing S, Schröck A, Bootz F, Brossart P, Kirfel J, Lengerke C, Perner S.

Int J Cancer. 2016 Nov 15;139(10):2359-69. doi: 10.1002/ijc.30279. Epub 2016 Jul 30.

36.

Survival and prognostic factors of patients with renal cell cancer with bone metastasis in the era of targeted therapy: A single-institution analysis.

Du Y, Pahernik S, Hadaschik B, Teber D, Duensing S, Jäger D, Hohenfellner M, Grüllich C.

Urol Oncol. 2016 Oct;34(10):433.e1-8. doi: 10.1016/j.urolonc.2016.05.017. Epub 2016 Jun 16.

PMID:
27321354
37.

Spatial niche formation but not malignant progression is a driving force for intratumoural heterogeneity.

Hoefflin R, Lahrmann B, Warsow G, Hübschmann D, Spath C, Walter B, Chen X, Hofer L, Macher-Goeppinger S, Tolstov Y, Korzeniewski N, Duensing A, Grüllich C, Jäger D, Perner S, Schönberg G, Nyarangi-Dix J, Isaac S, Hatiboglu G, Teber D, Hadaschik B, Pahernik S, Roth W, Eils R, Schlesner M, Sültmann H, Hohenfellner M, Grabe N, Duensing S.

Nat Commun. 2016 Jun 13;7:ncomms11845. doi: 10.1038/ncomms11845.

38.

MERTK as a novel therapeutic target in head and neck cancer.

von Mässenhausen A, Sanders C, Thewes B, Deng M, Queisser A, Vogel W, Kristiansen G, Duensing S, Schröck A, Bootz F, Brossart P, Kirfel J, Heasley L, Brägelmann J, Perner S.

Oncotarget. 2016 May 31;7(22):32678-94. doi: 10.18632/oncotarget.8724.

39.

IL-6 Overexpression in ERG-Positive Prostate Cancer Is Mediated by Prostaglandin Receptor EP2.

Merz C, von Mässenhausen A, Queisser A, Vogel W, Andrén O, Kirfel J, Duensing S, Perner S, Nowak M.

Am J Pathol. 2016 Apr;186(4):974-84. doi: 10.1016/j.ajpath.2015.12.009.

PMID:
27012192
40.

Adjuvant therapy for renal-cell carcinoma: settled for now.

Duensing S, Hohenfellner M.

Lancet. 2016 May 14;387(10032):1973-4. doi: 10.1016/S0140-6736(16)00653-X. Epub 2016 Mar 9. No abstract available.

PMID:
26969091
41.

Multiparametric Magnetic Resonance Imaging (MRI) and MRI-Transrectal Ultrasound Fusion Biopsy for Index Tumor Detection: Correlation with Radical Prostatectomy Specimen.

Radtke JP, Schwab C, Wolf MB, Freitag MT, Alt CD, Kesch C, Popeneciu IV, Huettenbrink C, Gasch C, Klein T, Bonekamp D, Duensing S, Roth W, Schueler S, Stock C, Schlemmer HP, Roethke M, Hohenfellner M, Hadaschik BA.

Eur Urol. 2016 Nov;70(5):846-853. doi: 10.1016/j.eururo.2015.12.052. Epub 2016 Jan 19.

PMID:
26810346
42.

Local salvage therapy for late (≥2 years) metastatic and local relapse of renal cell cancer is a potentially curative treatment irrespective of the site of recurrence.

Grüllich C, Vallet S, Hecht C, Duensing S, Hadaschik B, Jäger D, Hohenfellner M, Pahernik S.

Urol Oncol. 2016 May;34(5):238.e9-17. doi: 10.1016/j.urolonc.2015.11.022. Epub 2015 Dec 28.

PMID:
26739671
43.

Prognostic Significance and Functional Role of CEP57 in Prostate Cancer.

Mang J, Korzeniewski N, Dietrich D, Sailer V, Tolstov Y, Searcy S, von Hardenberg J, Perner S, Kristiansen G, Marx A, Roth W, Herpel E, Grüllich C, Popeneciu V, Pahernik S, Hadaschik B, Hohenfellner M, Duensing S.

Transl Oncol. 2015 Dec;8(6):487-96. doi: 10.1016/j.tranon.2015.11.004.

44.

Uncoupling of PUMA Expression and Apoptosis Contributes to Functional Heterogeneity in Renal Cell Carcinoma - Prognostic and Translational Implications.

Zhou X, Li J, Marx C, Tolstov Y, Rauch G, Herpel E, Macher-Goeppinger S, Roth W, Grüllich C, Pahernik S, Hohenfellner M, Duensing S.

Transl Oncol. 2015 Dec;8(6):480-6. doi: 10.1016/j.tranon.2015.11.003.

45.

The ribosomal protein S6 in renal cell carcinoma: functional relevance and potential as biomarker.

Knoll M, Macher-Goeppinger S, Kopitz J, Duensing S, Pahernik S, Hohenfellner M, Schirmacher P, Roth W.

Oncotarget. 2016 Jan 5;7(1):418-32. doi: 10.18632/oncotarget.6225.

46.

PBRM1 (BAF180) protein is functionally regulated by p53-induced protein degradation in renal cell carcinomas.

Macher-Goeppinger S, Keith M, Tagscherer KE, Singer S, Winkler J, Hofmann TG, Pahernik S, Duensing S, Hohenfellner M, Kopitz J, Schirmacher P, Roth W.

J Pathol. 2015 Dec;237(4):460-71. doi: 10.1002/path.4592. Epub 2015 Aug 19.

PMID:
26178300
47.

Analysis of centrosomes in human cancer.

Duensing S.

Methods Cell Biol. 2015;129:51-60. doi: 10.1016/bs.mcb.2015.03.002. Epub 2015 May 27.

PMID:
26175433
48.

The Impact of Magnetic Resonance Imaging on Prediction of Extraprostatic Extension and Prostatectomy Outcome in Patients with Low-, Intermediate- and High-Risk Prostate Cancer: Try to Find a Standard.

Radtke JP, Hadaschik BA, Wolf MB, Freitag MT, Schwab C, Alt C, Roth W, Duensing S, Pahernik SA, Roethke MC, Schlemmer HP, Hohenfellner M, Teber D.

J Endourol. 2015 Dec;29(12):1396-405. doi: 10.1089/end.2015.0358. Epub 2015 Aug 20.

PMID:
26154571
49.

[Metastasized prostate cancer. Position paper on the use of chemotherapy].

Ohlmann CH, Duensing S, Eichenauer R, König F, Machtens S, Schostak M, Thomas C, Albers P.

Urologe A. 2015 Jul;54(7):998-1001. doi: 10.1007/s00120-015-3841-0. German.

PMID:
25962469
50.

[Intratumoral heterogeneity in renal cell carcinoma. Molecular basis and translational implications].

Höfflin R, Roth W, Sültmann H, Grüllich C, Hatiboglu G, Nyarangi-Dix J, Schönberg G, Teber D, Hadaschik B, Pahernik S, Hohenfellner M, Duensing S.

Urologe A. 2015 Jun;54(6):800-3. doi: 10.1007/s00120-015-3800-9. Review. German.

PMID:
25758237

Supplemental Content

Loading ...
Support Center